International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 08 August 2023

Page No: 1573 -1577

DOI: https://doi.org/10.47191/ijmscrs/v3-i8-23, Impact Factor: 6.597

Systemic Scleroderma: A Deep Dive into the Complexity of a Multi-System Autoimmune Connective Tissue Disease

Lorena Estefani Alfaro García[1], María Erika Boza Medrano[2], Susana González Hernández[3], Manuel Alejandro Coello Manuell[4], Alma Yaneli Alvarez Romero[5]

[1]Hospital General de Zona #2 Dr. Efrén Correa Magallanes. Fresnillo, Zacatecas, México.

[2]Hospital general de zona #1 Instituto Mexicano del Seguro Social. Durango. Durango, México.

[3]Hospital General Dr. Dario Fernandez Fierro. Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Ciudad de México, México.

[4]Facultad de Medicina, Universidad Nacional Autónoma de México. México.

[5]Hospital General Regional 1 Tijuana Instituto Mexicano del Seguro Social, México.

ABSTRACT

Systemic scleroderma, a complex and rare autoimmune connective tissue disease, represents a significant clinical and scientific challenge due to its clinical heterogeneity, multisystem involvement, and potential for severe disability and complications. This article examines in depth the epidemiological, clinical, diagnostic and therapeutic aspects associated with this complex condition. Through a comprehensive review, it highlights the importance of a multidisciplinary medical approach to properly evaluate and manage the disease, from early detection to the implementation of specific therapeutic strategies targeting affected organs and systems. It also emphasizes the need for continued research to better understand the underlying pathogenic mechanisms and develop more effective therapies, with the goal of improving the outcomes and quality of life of patients affected by this complex autoimmune condition.

KEYWORDS: Scleroderma, autoinmune, disease

ARTICLE DETAILS

Published On:
09 August 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Scleroderma, also known as systemic sclerosis, is a rare and complex connective tissue disease that affects multiple body systems. It is characterized by excessive and abnormal accumulation of collagen in the skin and other organs, resulting in progressive sclerosis (hardening) and tissue dysfunction.1

This autoimmune condition, whose origin is not yet fully understood, sets in motion an aberrant immune response that triggers an inflammatory cascade and disruption of connective tissue homeostasis. As collagen is deposited in excess, the skin may become tight, thick and shiny, acquiring a characteristic sclerodactyly appearance, mainly affecting the extremities.1

Scleroderma is classified into two main forms: localized and systemic. The localized variant usually manifests in a more benign manner, mainly affecting specific areas of the skin, such as the hands, face and legs. On the other hand, the systemic form is more severe and affects multiple organs and Systems, including the lungs, heart, kidneys and gastrointestinal tract.1

EPIDEMIOLOGY

Scleroderma, a rare autoimmune connective tissue disease, is considered a public health challenge due to its complex nature and potentially devastating impact on patients' quality of life. The epidemiology of this condition involves the study of its prevalence, incidence and risk factors for a comprehensive understanding of its distribution and burden in the population.1,2

The prevalence of scleroderma varies significantly worldwide, showing geographic and ethnic differences. In general, systemic scleroderma is estimated to affect about 10-512 persons per million population in different regions, indicating its rare and dispersed nature. The highest prevalence rates have been observed in areas with higher concentrations of African-descent or Native American populations.1,2

In terms of incidence, scleroderma occurs most frequently in adults, with two peaks of incidence: one between the ages of 30 and 50 years, and the other between the ages of 60 and 80 years. Most new cases are diagnosed in women, with a gender ratio of approximately 3 to 8 women for every affected man. This gender disparity suggests the possible influence of hormonal and genetic factors in the development of the disease.1,2

The risk factors for scleroderma are not yet fully understood, but several aspects have been identified that may be associated with an increased risk of developing the disease. A genetic component has been observed in some cases, with the presence of a family history of autoimmune disease or scleroderma. In addition, exposure to certain environmental agents, such as silica, organic solvents and air pollutants, has been investigated as possible triggers of the disease.2,3

Importantly, although scleroderma can affect people of all ages and ethnic groups, some specific clinical variants, such as diffuse systemic sclerosis, appear to be more prevalent in certain ethnic groups, such as people of African descent. This indicates the need to consider genetic and ethnic factors when analyzing the epidemiology of the disease.3

Scleroderma, being a chronic and complex disease, carries important public health implications, including the economic burden associated with its long-term management and treatment. In addition, the lack of a definitive cure and the variability in the clinical presentation of the disease pose significant challenges for healthcare professionals in its diagnosis and therapeutic approach.3

CLINICAL RELEVANCE

Scleroderma emerges as a disease of high clinical and scientific relevance due to its pathological complexity, its multisystemic impact on patients' health and the difficulty of its early diagnosis and adequate therapeutic management. This autoimmune connective tissue condition presents a significant challenge for both health professionals and public health in general.3,4

First, scleroderma is characterized by its rare and scattered nature in the population, which requires adequate awareness and understanding on the part of physicians and other health care providers. Timely and accurate detection of early symptoms is essential for early diagnosis and proper management of the disease. However, due to the clinical heterogeneity of scleroderma and similarity to other rheumatologic conditions, its diagnosis may be delayed, leading to unfavorable disease progression and an increased burden of disability for the patient.3,4

In addition, scleroderma presents a variety of clinical manifestations, ranging from localized cutaneous involvement to systemic sclerosis with multiorgan damage. This complexity contributes to the need for a multidisciplinary medical approach to the comprehensive management of the disease, involving specialists in rheumatology, dermatology, cardiology, pulmonology, gastroenterology and other relevant fields. Collaboration among these experts is essential for a holistic approach in the treatment and follow-up of patients, with the aim of improving quality of life and preventing serious complications.4,5

In terms of public health impact, scleroderma poses significant economic challenges due to the high costs associated with long-term management and treatment of the disease. In addition, the disability and multi-organ dysfunction that can develop in advanced systemic sclerosis can affect patients' work productivity and quality of life, creating a burden for both affected individuals and their families and caregivers.4,5

Scientific research on scleroderma is essential to advance the understanding of the underlying mechanisms of the disease, which in turn would allow the development of more effective and targeted therapies. The identification of risk factors, the elucidation of immunological processes, and the search for diagnostic and prognostic biomarkers are crucial areas of study that could have a significant impact on the approach to scleroderma.5

CLINIC

Scleroderma, a complex systemic autoimmune disease of connective tissue, exhibits a varied and heterogeneous clinical presentation involving multiple body systems. Its clinical presentation is characterized by a diverse spectrum of manifestations ranging from localized cutaneous involvement to systemic sclerosis with multiorgan damage, which makes the diagnosis and management of this disease a challenge for healthcare professionals.6

Scleroderma can manifest itself in two main forms: localized and systemic. The localized variant, also known as morphea, is characterized by the appearance of sclerotic skin plaques of different sizes and shapes in specific areas of the skin, such as the trunk, extremities and face. These lesions may be circumscribed or diffuse, and in some cases may involve the underlying subcutaneous tissues and muscles.6

In contrast, the systemic form of scleroderma presents with more generalized, multisystem involvement. Patients with systemic sclerosis often experience Raynaud's phenomena as one of the first signs, characterized by color changes in the fingers and other extreme areas in response to cold or stress. In addition, sclerodactyly, which is the thickening and hardening of the skin of the fingers, is a distinctive finding in this form of the disease.7

As systemic scleroderma progresses, complications may arise in various organs and systems. Gastrointestinal system involvement can result in esophageal dysmotility, gastroesophageal reflux, and difficulty swallowing, which can lead to decreased food intake and malnutrition. Respiratory system dysfunction, such as progressive pulmonary fibrosis, can compromise respiratory function and increase the risk of pulmonary hypertension, a serious complication associated with high mortality rates.7

In addition, the heart may also be affected, leading to cardiac diseases such as cardiomyopathy and constrictive pericarditis. The kidneys may be vulnerable to vascular sclerosis, which can lead to high blood pressure and kidney failure. Muscles and joints may also suffer damage in the form of myositis and joint inflammation, contributing to physical disability.8

In systemic scleroderma, the presence of specific autoantibodies, such as anti-Scl-70 and anti-centromere antibody, may have prognostic implications and guide clinical evaluation and therapeutic management.7,8

The clinical course of scleroderma can be highly variable, with periods of activity and remission. Acute flares can trigger exacerbations of symptoms and clinical manifestations, underscoring the importance of careful monitoring and follow-up of patients.6

DIAGNOSIS

The diagnosis of scleroderma represents a clinical challenge due to its complexity and heterogeneity in clinical presentation. The diagnostic approach requires careful clinical evaluation, meticulous review of the medical history and the use of specific diagnostic tools to establish an accurate differential diagnosis with other rheumatologic diseases.8

The initial clinical history should include a detailed compilation of symptoms and disease duration, as well as a review of systems to identify any multisystem involvement. Patients with scleroderma may present with initial complaints of Raynaud's phenomena, skin changes such as sclerodactyly and sclerotic plaques, swallowing difficulties, dyspnea, and other symptoms associated with specific organs and systems.8

A thorough physical examination is essential to detect the hallmark signs of scleroderma. Careful observation of the skin for sclerotic changes, alterations in the fingers, and capillary changes in the nails, such as the capillaroscopic pattern, may be suggestive findings. In addition, palpation of internal organs, such as the lungs and heart, may reveal signs of multiorgan involvement.9

Systemic scleroderma is associated with the presence of specific autoantibodies, and the detection of these serological markers is essential in the diagnosis and classification of the disease. Anti-topo isomerase I antibodies (anti-Scl-70) and anticentromeric antibodies are the most relevant, and their presence may indicate an increased likelihood of systemic involvement and provide prognostic information.10

Pulmonary function tests, such as spirometry and diffusing capacity for carbon monoxide (DLCO), are crucial in assessing respiratory function and detecting potential pulmonary complications, such as pulmonary fibrosis. Echocardiography and other cardiac tests can help identify cardiac abnormalities, such as cardiomyopathy or constrictive pericarditis.11

In addition, the detection of esophageal dysfunction and other gastrointestinal disorders can be performed by tests such as esophageal manometry and endoscopy, providing valuable information on the involvement of the digestive system.12

In uncertain clinical situations or when the differential diagnosis with other rheumatologic diseases is complex, skin biopsy and histopathology may be used to examine the morphology and abnormal collagen accumulation in the skin, which may confirm the diagnosis of scleroderma.11,12,13

Early and accurate diagnosis of scleroderma is essential to allow timely and appropriate therapeutic management and prevention of serious complications. A comprehensive clinical approach, detailed evaluation of clinical manifestations and the use of specific diagnostic tools are fundamental pillars to establish an accurate diagnosis and improve the quality of life of patients affected by this complex autoimmune connective tissue condition.13,14

TREATMENT

The therapeutic management of scleroderma represents a clinical challenge due to its complexity and the multisystem involvement it can present. Since there is no definitive cure for this autoimmune connective tissue disease, the therapeutic approach focuses on controlling symptoms, preventing disease progression and treating complications that may arise.14

The treatment of scleroderma requires a multidisciplinary approach involving various specialists such as rheumatologists, dermatologists, cardiology, pulmonology, gastroenterology and other healthcare professionals. This comprehensive approach is essential to properly assess and manage the multisystem involvement of the disease.14

Patients with localized sclerosis, also known as morphea, may benefit from topical treatment with corticosteroids and immunomodulatory agents, such as tacrolimus or pimecrolimus, to reduce inflammation and skin thickening. In addition, ultraviolet A (UVA) or ultraviolet B (UVB) phototherapy may also be helpful in some cases of morphea.14

For systemic scleroderma, treatment focuses on symptom management and prevention of complications. Immunosuppressive drugs, such as methotrexate, cyclophosphamide, mycophenolate mofetil, and azathioprine, are used to inhibit the abnormal immune response and reduce systemic inflammation. Glucocorticoids, such as prednisone, can also be administered to control inflammation and acute symptoms.14

In cases of pulmonary involvement, treatment may include immunosuppressive therapies and the use of antifibrotic drugs, such as nintedanib and pirfenidone, to slow the progression of pulmonary fibrosis and improve respiratory function. Pulmonary hypertension associated with scleroderma can be treated with specific vasodilators, such as phosphodiesterase-5 (PDE-5) inhibitors and endothelin receptor antagonists. 14,15

Management of gastrointestinal complications involves changes in diet, the use of medications to control gastroesophageal reflux and esophageal dysmotility, and in some cases, surgical procedures may be required to relieve esophageal obstructions or strictures.15

In cases of cardiac involvement, medications may be used for blood pressure control and treatment of cardiomyopathy, and in severe cases, cardiac transplantation may be required.15

In addition to pharmacological treatment, physiotherapy and occupational therapy are important to maintain joint mobility and function, as well as to prevent contracture and physical disability.14,15

It is essential to emphasize that the treatment of scleroderma must be individualized for each patient, taking into account the extent and severity of the disease, as well as comorbidities and drug tolerance. Continued research in this area is essential to develop more effective and specific therapies targeting the underlying pathogenic mechanisms, with the goal of improving the outcomes and quality of life of patients affected by this complex autoimmune connective tissue condition.15

CONCLUSIONS

Scleroderma, a rare and complex autoimmune disease of the connective tissue, emerges as a clinical entity of great medical and scientific relevance due to its clinical heterogeneity, its multisystemic involvement and its potentially devastating impact on the quality of life of affected patients. Throughout this review, we have examined in detail the epidemiological, clinical, diagnostic and therapeutic aspects associated with this complex condition.

Scleroderma has a diverse clinical presentation, ranging from benign localized cutaneous forms to severe and life-threatening systemic manifestations. The diagnosis of this disease requires a thorough clinical evaluation, a detailed review of the medical history and the use of specific diagnostic tools, such as autoantibody screening, pulmonary function tests and skin biopsy. Due to the similarity with other rheumatologic diseases and its rarity, early and accurate diagnosis is essential for timely and appropriate therapeutic management.

The management of scleroderma involves a multidisciplinary approach involving various medical specialists to evaluate and address the multisystem involvement of the disease. Therapy focuses on symptom control, prevention of disease progression, and treatment of specific complications that may arise in affected organs and systems. The use of immunosuppressive drugs, glucocorticoids and other organ-specific therapies, such as antifibrotics and vasodilators, is fundamental in the therapeutic management of scleroderma.

Importantly, despite advances in the understanding of scleroderma, there are still significant gaps in the knowledge of the underlying pathogenic mechanisms. Continued scientific research is essential to unravel the complex immunological and molecular mechanisms involved in this disease and to develop more effective and targeted therapies that improve the outcomes and quality of life of affected patients.

In summary, scleroderma represents a medical entity of great complexity and clinical challenge that requires a comprehensive and continuous approach in its diagnosis, management and therapeutic approach. Collaboration between healthcare professionals, public awareness and scientific research are fundamental pillars in the fight against this complex autoimmune connective tissue condition, with the aim of improving the quality of life of affected patients and reducing their burden at the individual level.

REFERENCES

I. E.C. LeRoy, C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T.A. Medsger Jr, et al.Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol, 15 (1988), pp. 202-205.

II. L. Chung, J. Lin, D.E. Furst, D. Fiorentino. Systemic and localized scleroderma. Clin Dermatol, 24 (2006), pp. 374-392 http://dx.doi.org/10.1016/j.clindermatol.2006.07.004

III. H. Chifflot, B. Fautzi, C. Sordet, E. Chatelus, J. Sibilia. Incidence and prevalence of systemic sclerosis: A systematic literature review. Semin Arthritis Reum, 37 (2008), pp. 223-235.

IV. M.D. Mayes. Scleroderma epidemiology. Rheum Dis Clin North Am, 29 (2003), pp. 239-254. T.J. Laing, B.W. Gillespie, M.B. Toth, M.D. Mayes, R.H. Gallavan Jr. Gillespie, M.B. Toth, M.D. Mayes, R.H. Gallavan Jr, C.J. Burns, et al.

V. Racial differences in scleroderma among women in Michigan. Arthritis Rheum, 40 (1997), pp. 734-742 http://dx.doi.org/10.1002/1529-0131(199704)40:4<734::AID-ART20>3.0.CO;2-3

VI. R. Vancheeswaran, C.M. Black, J. David, N. Hasson, J. Harper, D. Atherton, et al.Childhood-onset scleroderma: Is it different from adult-onset disease. Arthritis Rheum, 39 (1996), pp. 1041-1049.

VII. K. Scalapino, T. Arkachaisri, M. Lucas, N. Fertig, D.J. Helfrich, A.V. Londino Jr, et al.Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol, 33 (2006), pp. 1004-1013.

VIII. K. Aoyama, Y. Nagai, Y. Endo, O. Ishikawa. Juvenile systemic sclerosis: report of three cases and review of Japanese published work. J Dermatol, 34 (2007), pp. 656-658.

IX. G.F. Mora. Systemic sclerosis: Environmental factors. J Rheumatol, 36 (2009), pp. 2383-2396 http://dx.doi.org/10.3899/jrheum.090207

X. E. Fonseca. Cutaneous manifestations of toxic syndrome due to adulterated rapeseed oil. Actas Dermosifiliogr, 100 (2009), pp. 857-860.

XI. L.D. Kaufman, R.J. Seidman, M.E. Phillips, B.L. Gruber. Cutaneous manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome: A spectrum of sclerodermatous skin disease. J Am Acad Dermatol, 23 (1990), pp. 1063-1069.

XII. J.D. Reveille. Ethnicity and race and systemic sclerosis: How it affects susceptibility, severity, antibody genetics and clinical manifestations. Curr Rheumatol Rep, 5 (2003), pp. 160-167.

XIII. J.D. Reveille, M. Fischbach, T. McNearney, A.W. Friedman, M.B. Aguilar, J. Lisse, et al.Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic and immunogenetic determinants. Semin Arthritis Rheum, 30 (2001), pp. 332-346 http://dx.doi.org/10.1053/sarh.2001.20268

XIV. N.S. Gendi, K.I. Welsh, W.J. Van Venrooij, R. Vancheeswaran, J. Gilroy, C.M. Black.HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum, 38 (1995), pp. 259-266.

XV. F.C. Arnett.HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol, 12 (1995), pp. 107-128.